Two linked studies published in the New England Journal of Medicine report encouraging results for a gene therapy targeting Wiskott–Aldrich syndrome, a rare and life-threatening condition affecting the immune system.
The New England Journal of Medicine has published findings from two clinical trials — a phase 1–2 study called TIGET-WAS and a phase 3 study called OTL-103-4 — examining a gene therapy known as etuvetidigene autotemcel as a treatment for Wiskott–Aldrich syndrome (WAS).
WAS is a rare inherited condition caused by a faulty gene that disrupts how the immune system and blood-clotting cells (platelets) work. It affects almost exclusively boys and can leave them seriously vulnerable to infections, bleeding, and autoimmune problems. The therapy works by taking a patient’s own stem cells, correcting the genetic fault in a laboratory, and returning them to the body — a process known as autologous gene therapy.
The research is tagged under haematology — the study of blood disorders — and genetics, reflecting the dual nature of the condition and its treatment.
Because WAS is rare, large-scale trials are difficult to run. The progression from a phase 1–2 safety and early-efficacy study to a phase 3 trial represents a meaningful step in the development pathway for this therapy. Phase 3 trials are typically the final stage before a treatment is considered for regulatory approval.
The full findings, including patient numbers, response rates, and safety data, are available in the journal. The New England Journal of Medicine is a peer-reviewed publication and one of the most widely cited medical journals in the world.
Source: @NEJM